The availability of small molecules like DRB-18 or BAY-876, the presence of antisense cDNA therapy, anti-GLUT antibodies, and even naturally derived pan-GLUT inhibitors appears to be the current direction [192], requiring further investigation and application in the context of PCa progression. The gene discussed is SLC2A1; the disease is posterior cortical atrophy.